Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung15: Datopotamab deruxtecan with or without osimertinib versus platinum doublet chemotherapy after osimertinib progression in EGFR-mutated non-squamous NSCLC
MOH_2025-01-19_013855Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan and osimertinib in Non-small cell lung cancer (NS-NSCLC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
datopotamab deruxtecanosimertinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on MOH_2025-01-19_013855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-19_013855.